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well-being. Exenatide: no PRO US/EU label claims sought. Lorcaserin: PRO-data 
supported US-approval (no label-claim). PRO-data supported MA for the UK and 
US. Key findings from payer interviews (n= 6 EU/n= 4 US) revealed that health-
care-system differences influence payer-preferences for PRO-type (e.g., generic/
disease-specific), influenced primarily by need for cost-effectiveness model. All 
payers stated that PRO-data provide unique perspective on condition/treatment 
but considered reimbursement difficult to influence; although stated that PRO-data 
can positively impact prescribing/MA. Payers reported that in EU, PROs are part of 
the clinical-evidence considered by HTA reviewing committees. Utility data derived 
from generic instruments are essential for key EU-markets (excluding Germany). 
US health plans are interested in PRO measures that are tied to “actionable” end-
points (e.g., adherence/persistence, tolerability, reduction in costs or resource 
utilisation). CONCLUSIONS: Key drivers for a successful PRO strategy include the 
development of robust PRO and communication strategy tailored to the needs/
requirements of the end-users (regulators, HTA and MA). Sponsors must continue 
to bring data based on robust PROs to regulators, HTA and MA and thus bringing 
the patient, the most affected stakeholder, to the forefront in decision making.
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OBJECTIVES: To assess current status of disease control and treatment satisfaction 
in patients with acromegaly in the United States. METHODS: A web-based cross-
sectional survey was conducted from August –October, 2014. Acromegaly patient-
reported information on treatment satisfaction and preference, symptom control, 
and comorbidities were collected and analyzed descriptively. RESULTS: A total of 
106 patients completed the survey (mean age: 46 years, female: 76%). Patients had 
a 5-year diagnosis delay after symptom onset. Most patients (91%) had undergone 
surgery. Of 68 patients on pharmaceutical therapy: 79% were on somatostatin ana-
logs, 22% on dopamine agonists and 13% on GH-receptor antagonists. Almost half 
of the patients (47/106) presented with 5 or more comorbidities (depression 57%, 
hypertension 43%, musculoskeletal and connective tissue abnormalities 42%, sleep 
apnea 37%, cardiac and cardiovascular diseases 32%, and diabetes 32%). There were 
96 (91%) patients reporting acromegaly-related symptoms (e.g. headache, excess 
sweating, and joint pain). As compared with the low-symptom group 0-3 (n= 41), the 
high-symptom group with 4+ symptoms (n= 65) were more likely to have depression 
(OR= 2.33, 95% CI, 1.05-5.19) and cardiovascular disease (OR= 5.80, 95% CI, 2.02-16.67). 
Among patients on injectables (n= 61), 61% had worse symptoms toward the end of 
injection cycle, and 38% requested medical intervention (i.e. additional daily injec-
tion, unscheduled injection, or oral medicines). 84% of patients reported that the 
symptoms interfered with daily life and work; 85% felt frustrated. The treatment 
satisfaction rate was 56%; 33% didn’t like having injections. The top patients’ prefer-
ences for new acromegaly treatments were to avoid injections (e.g., oral formula-
tion) (85%), improve disease management such as patients’ support (62%), and to 
provide better patient education (57%). CONCLUSIONS: More than 40% of patients 
were not satisfied with their current treatment for acromegaly. Patients want better 
therapy (e.g., oral drugs), improved disease management, and education programs.
PDB74
assesment of Dietry knowLeDge, myths anD misconcePtions among 
DiaBetic Patients
ul Haq N.1, Akbar N.1, Iqbal Q.1, Naseem A.1, Azhar S.A.2, Bashir S.3
1University of Balochistan, Quetta, Pakistan, 2COMSATS Institute of Information Technology, 
Abbottabad, Pakistan, 3University of Sargodha, Sargodha, Pakistan
OBJECTIVES: The present study aimed to assess the dietary knowledge, myths and 
misconceptions among diabetic patients in Quetta, Pakistan. METHODS: The study 
was conducted as a cross sectional, questionnaire based study covering diabetic 
patients in public and private hospitals and diabetic clinics of Quetta city, Pakistan. 
A self-administered questionnaire was used evaluate the dietary knowledge, myths 
and misconception about diabetes. The questionnaire constructed with a total of 20 
(10 questions each for dietary knowledge, myths and misconception). Continuous 
variables were expressed as mean ± SD, and categorical variables are represented 
in frequency and percentage. RESULTS: A total of 400 questionnaires were dis-
tributed out of which 320 were received and included in the study. The study is 
dominated with male respondents (59.7%, n= 191), with majority (37.2%, n= 119) 
categorised in age group between 25-34 years and married (78.4%, n= 251) with 
education level as S.S.C (matriculation) (39.1%, n= 125). The mean dietary knowledge 
score was 4.81± 1.2 and myths and misconception score was 3.32± 1.8 both catego-
rised as poor. CONCLUSIONS: The study concluded that diabetes patients has poor 
knowledge regarding dietary knowledge and has high prevalence of dietary myths 
and misconceptions. Patients should be educated for proper dietary changes to be 
adopted for better disease control.
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OBJECTIVES: An important characteristic of successful healthcare and patient 
participation in clinical trials is strong communication between patients and 
their providers. Using e-clinical technology can be one mechanism for achieving 
this goal. We propose that the optimal implementation considers patient prefer-
ence and ease of use, and that incorporating e-clinical technology can lead to 
increased patient compliance and ultimately improved clinical care. METHODS: 
We surveyed 105 patients in the U.S. with diabetes; questions focused on mobile 
technology use, perceptions, and preferences. RESULTS: Patients were diverse in 
tion value= 0.75, and negative prediction value= 0.62. Temporal validation showed 
decrease in the sensitivity (0.69) and specificity (0.60) statistics. CONCLUSIONS: 
RxAPT shows promise as an effective tool to identify patients who are likely to 
become non-adherent to diabetes medications in the follow-up year. Further valida-
tion is needed before the tool can be implemented in a real world setting.
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OBJECTIVES: This study describes the relationship between health-related quality of 
life (HR-QoL) assessed using the SF-36v2 and adherence as measured by the Morisky 
Medication Adherence Scale (4-item MMAS-4 , 8-item MMAS-8, and a 4-item scoring 
of the MMAS-8) among US adults with type 2 diabetes (T2D). METHODS: Data were 
taken from the 2011 and 2012 US National Health and Wellness Survey (NHWS). The 
NHWS is a large cross-sectional survey representative of the total adult population 
in several major markets; N~75,000/year in the US. A total of 13,007 respondents 
self-reported physician diagnosis of T2D and were administered MMAS-4 in 2011 
or MMAS-8 in 2012. The relationship between SF-36v2 measures and adherence 
was described for the two adherence scales and also a scoring of the MMAS-8 that 
uses only the 4 items best matched to the questions in the MMAS-4. RESULTS: In 
T2D patients, MMAS-4 resulted in a greater percentage of respondents classified as 
having high adherence than MMAS-8 (64% vs. 44%) and a lower percentage of low 
adherence (3% vs. 19%), while medium adherence was fairly similar (33% vs. 37%). 
The 4-item scoring of the MMAS-8 was more similar to MMAS-4 (79% high, 15% 
medium, 6% low). In OLS regressions controlling for sociodemographic characteris-
tics (e.g. age, gender, comorbidities, education, income), all measures of adherence 
were significant predictors of HR-QoL, with two main differences: R-squared values 
were slightly lower for regressions including MMAS-4 adherence and MMAS-4 was 
not predictive of Physical Component Summary (PCS) scores. CONCLUSIONS: All 
three adherence scores are significantly correlated with the Mental Component 
Summary and SF-6D health utility scores of the SF-36v2, MMAS-4 fails to correlate 
with PCS. The variation in proportion of patients classified as highly adherent across 
scales also suggests pooling such classifications across data using different versions 
of the MMAS is not advisable, at least among T2D patients.
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OBJECTIVES: Type 2 diabetes (T2D) is a chronic condition with well-described long-
term cardiovascular consequences and other co-morbidities. This study investigated 
the short-term impact of poor glycemic control on T2D patients’ daily lives to help 
define the health states for inclusion in a time trade off study (TTO). METHODS: 
Adult respondents in Denmark receiving medical treatment for T2D, and knowing 
their HbA1c level, completed an online survey based on results from prior telephone 
interviews with patients to identify perceptions on weight, simplicity of insulin 
regimen and aspects of well-being affected by change in HbA1c. Questions covered 
demographics and insulin regimen, most recent HbA1c and change from previous 
HbA1c, how often they experience certain physical and psychological symptoms 
(1–5 with 1= never and 5= always), if respondents wanted to reduce HbA1c, and the 
extent to which key criteria were felt to prevent reducing HbA1c (1–5 with 1= full 
extent and 5= not at all). RESULTS: 268 respondents (72% men, mean age 66.5 years) 
completed the survey. Average change in HbA1c was 2.0%. Frequency of excessive 
thirst reduced significantly with a > 1% drop in HbA1c and the effect increased with 
further decreasing HbA1c. Similar results were found for frequency of urination. 
Fatigue and lack of energy also improved with decreasing HbA1c. Almost 100% 
of respondents with HbA1c ≥ 9% wished to reduce their HbA1c, compared to 61% 
with HbA1c < 7%. Answering “to what extent does the following explain why your 
HBA1c is not lower?”, the highest response was ‘to avoid gaining weight’, lowest 
response was ‘forgetting to take medication’. CONCLUSIONS: Symptoms improve 
with reduced HbA1c, and the majority of respondents wish to lower their HbA1c. 
Changes in HbA1c are perceived to have a major impact on daily lives; however, 
there are still a variety of barriers preventing people with T2D from lowering their 
HbA1c.
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OBJECTIVES: To identify key drivers for the successful integration of patient-
reported outcomes (PROs) in clinical programs designed to support regulatory label 
claims, health technology assessment (HTA) and market access (MA) in diabetes 
and obesity. METHODS: Reviews of published literature, regulatory, HTA and third-
party websites were conducted to elicit key components of PRO strategies employed 
for two case examples: exenatide (diabetes) and lorcaserin (obesity). Qualitative 
one-on-one interviews were also conducted with payer decision-makers in key 
European (EU) and United States (US) markets to determine their perceptions of 
successful PROs strategies. RESULTS: Although there is an FDA draft guidance on 
PROs to support labeling claims, no disease-specific guidance on PRO-endpoints 
for obesity/diabetes are issued by FDA or EMA. Registration-trials included assess-
ments of; symptoms/health-related-quality-of-life/depression/psychological-
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24% wanted HCPs to talk about factors besides HbA1c. Further, while 44% of HCPs 
interviewed said the easiest way to achieve control was intensifying medication, 
patient’s often associated intensification and/or complex medication regimens as 
a negative aspect of control. CONCLUSIONS: The concept of “being in control” has 
multiple meanings to patients and these definitions are often at odds with HCP 
definitions. This discordance may result in suboptimal patient-HCP interactions 
as well as contribute to physician inertia to initiate and/or intensify treatments. 
Patient education and research is needed to better understand the management 
of uncontrolled diabetes.
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OBJECTIVES: Although literature on EQ-5D in T2DM indicates sensitivity to long-
term complications of the disease, Phase 3 trials, which by necessity are of short 
duration, have failed to detect changes in EQ-5D. The objective of this study was to 
examine if the traditional mean difference approach obscured meaningful changes 
in EQ-5D in a clinical trial of canagliflozin versus glimepiride in dual therapy with 
metformin. METHODS: Mean change in EQ-5D was calculated from baseline to 
Week 52. The empirical distribution of individual change scores was examined to 
assess how well the mean reflected individual experience. Comparisons of clinical 
and patient-reported outcomes (PROs) were performed across subgroups based 
on EQ-5D change (improve, decline, no change) to explore potential correlates of 
response. RESULTS: Mean change in EQ-5D among patients with both data points 
(N = 1,070) was 0.01 with a standard deviation of 0.2, indicating no difference from 
zero. The empirical distribution revealed that only 43.6% of patients had no change, 
while 33.4% improved and 23.0% declined. Decliners were more likely to be female 
(51.6% vs 40.5%), have a history of depression (9.3% vs 5.7%), lower baseline A1C (7.6% 
vs 7.8%), and worse baseline PROs versus those with no change. They also had more 
symptomatic hypoglycemic episodes (20.5% vs 13.7%) and poorer PRO responses. 
Improvers were more likely to be female (50.7% vs 40.5%) and to have worse PROs 
at baseline versus those with no change. They were also more likely to avoid weight 
gain (75.4% vs 69.2%) and symptomatic hypoglycemic episodes (84.5% vs 66.7%), as 
well as report greater improvements in PROs. CONCLUSIONS: This analysis sug-
gests that the mean change in EQ-5D may not sufficiently reflect patient experience 
in clinical trials of T2DM, and that patient-relevant factors such as weight change 
and symptomatic hypoglycemia are likely to be important predictors of response.
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OBJECTIVES: Medication adherence in patients with metabolic syndrome is vital 
for disease control. It is important to recognize patients’ barriers of adherence to 
improve outcomes. The objective of the study is to assess how patient self-reported 
barriers to adherence affect the pill counts of their medications and patient adher-
ence. METHODS: Appointments were held with 30 adult, English speaking patients, 
having type II diabetes, hypertension, hyperlipidemia, at least one oral medication 
for each disease state, and a minimum of five oral prescription medications. Pill 
counts were conducted, and patients were verbally asked seven questions targeting 
adherence barriers with responses assessed using a 4-point Likert-type scale from 
(1) Disagree completely to (4) Agree completely. Some questions included, “In the 
past two weeks, I forgot to take my medication at least once,” “I believe medicines do 
more harm than good.” Patients were placed into seven groups based on responses. 
Patients reporting more than one barrier were placed in multiple groups and pill 
counts of each group were averaged. Groups were analyzed to determine how barri-
ers influence pill count scores. Groups with pill count scores > .80 were determined 
to be adherent. RESULTS: The barrier, “forgot to take my medication,” was the most 
acknowledged of all barriers (N= 12) with a pill count score of .59, conversely (N= 18), 
.52. The least acknowledged barrier “I stop my medication if I do not feel it working” 
(N= 1) had a score of .94, conversely (N= 28), .52. Eight patients did not acknowledge 
any barriers with a pill count score of .44. CONCLUSIONS: Patients’ scores reflected 
that although patients did not report experiencing a barrier, they were non-adherent 
to their medications. Patients may misreport barriers, or not realize the barriers 
affecting them. Healthcare professionals must improve communication targeting 
adherence barriers specific to the patient to improve health outcomes.
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OBJECTIVES: Children with Growth Hormone Deficiency (GHD) can experience 
physical symptoms and limitations as well as a range of social and emotional prob-
lems. Unfortunately, no GHD specific measures exist to assess these impacts. This 
qualitative study identified key symptoms/impacts of GHD disease and treatment 
in order to support the development of a patient-reported outcome measure (PRO) 
for children ages 10-13 and an observer-reported outcome measure (ObsRO) for 
parents/guardians of younger children. METHODS: Focus groups and interviews 
were conducted with 39 children (age 8 -12) with GHD and 34 parents of children (age 
4 to 12) in 3 countries (Germany, UK US). All interviews were transcribed, analyzed, 
and coded thematically using adapted grounded theory to determine overarching 
themes and concepts. Based on the analysis, expert interviews and literature review, 
a conceptual model of GHD impacts was developed. RESULTS: Qualitative analy-
sis found saturation of concepts was reached with 3 domains of impact: Physical, 
Social, and Emotional. Sub-concepts included strength/endurance (48%), appetite 
age, sex, ethnicity, and smartphone ownership. Approximately 67% of patients 
had a computer at home. More than 65% reported interest in using electronic 
methods to interact more with their physician between visits to help manage 
and treat their disease. Patients reported that they were more likely to speak 
with their physician (46%), report disease symptoms (38%), report on their quality 
of life (37%), and take medication (32%) if they had more knowledge about their 
disease. When asked about the most effective way of improving their health and 
managing their disease, 32% responded “increasing communication and interac-
tions between my physician and me”; another 31% were interested in monitoring 
their disease, symptoms, and/or medications electronically so that their physician 
could see their health status in real time. Patients preferred electronic methods of 
managing their disease, including email and text message communications with 
their healthcare provider (73%), clinical visit scheduling via smartphone (76%), 
and medication reminders via smartphone (83%). CONCLUSIONS: Patients are 
interested in using electronic methods to increase communication with their phy-
sician and manage their disease. Possible opportunities for addressing this need 
include educational smartphone apps, medication reminders via text messaging, 
and clinic visit scheduling via smartphone. Providers should consider engaging 
patients with e-clinical technology to increase patient-physician communication 
and for the ultimate goal of improved healthcare.
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OBJECTIVES: To assess the preferences of Spanish and Portuguese patients and 
physicians regarding T2DM treatments and the monthly willingness to pay (WTP) 
for gaining benefits or avoiding side effects. METHODS: An observational, multi-
center, exploratory study focused on routine clinical practice in Spain and Portugal. 
Professionals were recruited from diverse hospitals and outpatient’s clinics while 
patients were recruited from 11 centers operating in the public healthcare system 
in different autonomous communities in Spain and in Portugal. Preferences were 
measured via a discrete choice experiment. Data was analyzed using a conditional 
logit model. RESULTS: 221 professionals from the Spanish and Portuguese NHS [62% 
female; mean age 41.9 (SD: 10.5); 33.5% endocrinologists, 66.5% GP] and 330 patients 
[49.7% female; mean age 62.4 (10.1), mean disease duration 13.98 (8.22) years, mean 
BMI 32.50 (6.82), 41.8% received oral + injected medication, 40.3% received oral and 
17.6% injected treatments] participated. Professionals placed the most value on 
avoiding one hypoglycemia per week [WTP: 287.18€ (95% CI: 160.31 - 1,387.21)], 
followed by avoid gaining 3 Kg/6 months and decreasing cardiovascular risk [WTP: 
166.87€ (88.63 - 843.09) and 154.30€ (98.13 - 434.19), respectively]. Patients placed 
the most value on the weight attribute [WTP: 68.14€ (54.55 - 85.08) to avoid gaining 
3 kg/6 months], followed by avoiding one hypoglycemic event per month [WTP: 
54.80€ (23.29 - 82.26)]. Professionals and patients were willing to pay 125.92€ (73.30 
– 622.75) and 24.28€ (18.41 – 30.31), respectively, to avoid increasing 1% of HbA1c 
and 143.30€ (73.39 – 543.62) and 42.74€ (23.89 – 61.77), respectively, for avoiding 
nausea. CONCLUSIONS: Both patients and professionals in Spain and Portugal are 
willing to pay for the health benefits associated with improved diabetes treatment, 
being the most important avoiding hypoglycemia and gaining weight. Decrease in 
cardiovascular risk and weight reduction became the third most valued attributes 
for professionals and patients, respectively.
PDB77
Defining uncontroLLeD DiaBetes from the Patient PersPective: a 
four-country stuDy in PeoPLe with tyPe-2 DiaBetes on BasaL insuLin
Brod M.1, Fisher C.1, Barnett A.H.2, Berntorp K.3, Vilsbøll T.4, Weissenberger B.5
1The Brod Group, Mill Valley, CA, USA, 2Birmingham Heartlands Hospital, Birmingham, UK, 3Lund 
Univerity, Department of Endocrinology, Skane University Hospital, Malmo, Sweden, 4Gentofte 
Hospital, University of Copenhagen, Hellerup, Denmark, 5FMH Endokrinologie und Diabetologie, 
Basel, Switzerland
OBJECTIVES: This qualitative study was conducted to address critical gaps on 
how type-2 diabetes patients using basal insulin understand the concept of their 
diabetes “being in control”. METHODS: Forty-nine type-2 diabetes patients on 
basal insulin (focus groups N= 45, individually N= 4) and 9 health care provid-
ers (HCPs), were interviewed in Sweden, Denmark, UK, and Switzerland. Patients 
were asked about their understanding of control, obstacles to achieving and how 
their understanding of control compared with their HCP. The interviews were 
transcribed, coded and qualitatively analyzed, based on grounded theory, to iden-
tify and quantify emerging themes. RESULTS: The mean age of patients was 64 
(range 28-83) with approximately 50% considering their diabetes out of control. 
In contrast to the accepted medical definition of control based on HbA1c (average 
plasma glucose value), 58% of patients associated diabetes control with factors 
other than HbA1c; 80% associated control with daily or hourly meter readings; 76% 
day-to-day feelings; 40% sugar fluctuations, and 38% with limitations in daily life. 
Major obstacles to control were: managing diet/appetite: 87%; inadequate educa-
tion from HCPs: 71%; lack of social support and schedule and lifestyle issues: 69%. 
Only 42% of patients mentioned medication regimen as affecting control. Twenty-
seven percent felt they had different definitions of control than their HCPs, and 
